Fujifilm Pharmaceuticals U.S.A.

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Fujifilm Pharmaceuticals U.S.A. sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Fujifilm Pharmaceuticals U.S.A.: 8 sponsored US clinical trials, none currently recruiting.

Fujifilm Pharmaceuticals U.S.A. sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumors, with 2 trials.

Upper-quartile sponsor footprint

Fujifilm Pharmaceuticals U.S.A. sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

NCT05318573
ACTIVE NOT RECRUITING Phase 1

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma

NCT04047251
ACTIVE NOT RECRUITING Phase 1

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer

NCT03440450
COMPLETED Phase 2

Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19

NCT04358549
COMPLETED Phase 1

Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03194685
COMPLETED Phase 1

A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer

NCT02454010
COMPLETED Phase 1

Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas

NCT02661542
COMPLETED Phase 1

Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

NCT02193958

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 2

Therapeutic Areas

Advanced Solid Tumors 2
Advanced Urothelial Carcinoma 1
Advanced Non-Small-Cell Lung Cancer 1
Merkel Cell Carcinoma 1
Biliary Tract Cancer 1
Solid Tumor 1

How the Fujifilm Pharmaceuticals U.S.A. early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Advanced Solid Tumors (2 trials), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Fujifilm Pharmaceuticals U.S.A.: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Fujifilm Pharmaceuticals U.S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Fujifilm Pharmaceuticals U.S.A.AB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Fujifilm Pharmaceuticals U.S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Fujifilm Pharmaceuticals U.S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Fujifilm Pharmaceuticals U.S.A. page

8 registered trials is a research-attention snapshot, not an endorsement of Fujifilm Pharmaceuticals U.S.A. or any single study.

  • None of Fujifilm Pharmaceuticals U.S.A.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Advanced Solid Tumors is the condition Fujifilm Pharmaceuticals U.S.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Fujifilm Pharmaceuticals U.S.A. pipeline card: 8 registered trials from official public datasets.Report a data error.